Join Philanthropy California for an overview of the impacts of COVID-19 in our state and a shared discussion about how individuals and institutions can support nonprofit organizations in their response and those individuals who are most impacted -- low income families, health-compromised individuals, small businesses, and more. We are together as part of a thriving community of funders with a strong giving spirit. This call draws on that strength to connect us all and answer questions, and prepare us for a robust response now and in the months to come. For more about Philanthropy California's response to COVID-19, please visit our website.
COVID-19: Treat, Cure, Prevent
Philanthropy is funding solutions for those hit hardest and falling through the cracks. Many of those people will struggle to simply pick up where they left off. But when will that return be and what will it look like?
Deciding when and how to resume daily activities relies, in large part, on treatments and a reliable vaccine to COVID-19. California hosts premier research institutions working on this question and this week we feature Scripps Research Institute.
We'll explore therapeutic treatments and the path to a vaccine for COVID-19. With the mission-driven perspective of a nonprofit institute, these researchers will address not just the science of COVID-19, but the ethics of equitable access to the results of their work.
Peter Schultz, PhD, is the president and chief executive officer of Scripps Research, ranked by Nature Index as the top nonprofit scientific institute in the U.S. and second in the world for the exceptional quality of its research. Under his leadership, Scripps Research has expanded its capabilities and implemented bold programs to intensify focus on a critical mission: accelerate the delivery of life-changing drugs to patients in need.
Dennis Burton, PhD, co-chair of the Department of Immunology & Microbiology at Scripps Research, is an expert in the interplay of viruses and antibodies. He and his laboratory team are analyzing blood samples from patients who have recovered from COVID-19, searching for antibodies that might be used as much-needed therapeutics or to help design a vaccine to protect against the disease.
Arnab Chatterjee, PhD, is vice president of medicinal chemistry at Calibr, the drug development division of Scripps Research. Calibr houses ReFRAME, a world-leading collection of over 14,000 drugs already proven safe in humans. These drugs can often be expediently repurposed to treat other diseases, including viral diseases such as COVID-19.
This program is open to NCG, SCG, and SDG members and non-member funders.